Lars Dyrskjot
Overview
Explore the profile of Lars Dyrskjot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
172
Citations
8424
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tateo V, Cigliola A, Mercinelli C, Agarwal N, Grivas P, Kamat A, et al.
Clin Genitourin Cancer
. 2024 May;
22(4):102091.
PMID: 38735133
Background: The application of precision medicine in clinical practice implies a thorough evaluation of actionable genomic alterations to streamline therapeutic decision making. Comprehensive genomic profiling of tumor via next-generation sequencing...
12.
Frydendahl A, Heilskov Rasmussen M, Jensen S, Vesterman Henriksen T, Demuth C, Diekema M, et al.
Int J Mol Sci
. 2024 Apr;
25(8.
PMID: 38673836
Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the crude error rate...
13.
Nesic M, Rasmussen M, Henriksen T, Demuth C, Frydendahl A, Nordentoft I, et al.
Int J Cancer
. 2024 Apr;
155(5):925-933.
PMID: 38623608
Tumor-informed mutation-based approaches are frequently used for detection of circulating tumor DNA (ctDNA). Not all mutations make equally effective ctDNA markers. The objective was to explore if prioritizing mutations using...
14.
Anurag M, Strandgaard T, Kim S, Dou Y, Comperat E, Al-Ahmadie H, et al.
iScience
. 2024 Mar;
27(3):109179.
PMID: 38439961
Urothelial carcinoma (CIS) is an aggressive phenotype of non-muscle-invasive bladder cancer. Molecular features unique to CIS compared to high-grade papillary tumors are underexplored. RNA sequencing of CIS, papillary tumors, and...
15.
Lobo N, Duan Z, Sood A, Tan W, Grajales V, Contieri R, et al.
Eur Urol Oncol
. 2024 Feb;
7(5):1069-1079.
PMID: 38302322
Background: Age disparity in patients with non-muscle-invasive bladder cancer (NMIBC) exists. Whether this is due to differences in adequate cancer care or tumour biology is unclear. Objective: To investigate age...
16.
Linscott J, Meeks J, Dyrskjot L, Li R
Eur Urol
. 2024 Jan;
85(4):317-319.
PMID: 38278663
Urinary tests for circulating tumor DNA have potential for accurate discrimination of bladder cancer from other common inflammatory processes. Efforts are still needed to determine whether these tests can differentiate...
17.
Elbaek S, Andreasen T, Taber A, Young-Halvorsen K, Neijber A, Jensen J, et al.
Eur Urol Open Sci
. 2023 Dec;
58:37-46.
PMID: 38152487
Background: Transurethral resection of bladder tumor (TURBT) is a central component in the diagnosis of non-muscle-invasive bladder cancer (NMIBC) and can be guided by several optical imaging techniques for better...
18.
Dyrskjot L, Hansel D, Efstathiou J, Knowles M, Galsky M, Teoh J, et al.
Nat Rev Dis Primers
. 2023 Oct;
9(1):58.
PMID: 37884563
Bladder cancer is a global health issue with sex differences in incidence and prognosis. Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is...
19.
Lyskjaer I, Iisager L, Axelsen C, Nielsen T, Dyrskjot L, Fristrup N
Clin Cancer Res
. 2023 Oct;
30(4):663-672.
PMID: 37874628
The incidence of renal cell carcinoma (RCC) is increasing worldwide, yet research within this field is lagging behind other cancers. Despite increased detection of early disease as a consequence of...
20.
Lindskrog S, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4797-4807.
PMID: 37782315
Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full...